News -

Latest News

in News
Hot shots named in Trump’s Warp Speed drive for coronavirus vaccine
June 5, 2020 Share
X
Hot shots named in Trump’s Warp Speed drive for coronavirus vaccine
https://pharmaphorum.com/news/hot-shots-named-in-trumps-warp-speed-drive-for-coronavirus-vaccine/
in News
PureTech unit Follica cues up phase 3 programme for male hair loss
June 4, 2020 Share
X
PureTech unit Follica cues up phase 3 programme for male hair loss
https://pharmaphorum.com/news/puretech-unit-follica-cues-up-phase-3-programme-for-male-hair-loss/

Gilead’s remdesivir could be $7.7bn blockbuster – analyst

An influential analyst has upped his previously cautious assessment of the sales potential of Gilead’s COVID-19 drug remdesivir, saying

Gilead’s remdesivir could be $7.7bn blockbuster – analyst

https://pharmaphorum.com/news/gileads-remdesivir-could-be-7-7bn-blockbuster-analyst/

FDA clears emergency use of Roche test for COVID-19 ‘cytokine storm’

Roche has been given a green light by the FDA to use one of its diagnostic tests to

FDA clears emergency use of Roche test for COVID-19 ‘cytokine storm’

https://pharmaphorum.com/news/fda-clears-emergency-use-of-roche-test-for-covid-19-cytokine-storm/

BMS launches COVID-19 delayed MS drug Zeposia in US

Bristol-Myers Squibb opted not to launch its new multiple sclerosis therapy Zeposia when it got FDA approval in

BMS launches COVID-19 delayed MS drug Zeposia in US

https://pharmaphorum.com/news/bms-launches-covid-19-delayed-ms-drug-zeposia-in-us/

See all

More news

AZ claims FDA okay for Brilinta in coronary artery disease patients

AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first

AZ claims FDA okay for Brilinta in coronary artery disease patients

https://pharmaphorum.com/news/az-claims-fda-okay-for-brilinta-in-coronary-artery-disease-patients/

Novartis closes on EU approval for breast cancer drug Piqray

Novartis has moved nearer to claiming approval for its PI3K inhibitor Piqray for breast cancer in the EU,

Novartis closes on EU approval for breast cancer drug Piqray

https://pharmaphorum.com/news/novartis-closes-on-eu-approval-for-breast-cancer-drug-piqray/

NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell

NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink

https://pharmaphorum.com/news/nice-recommends-roches-tecentriq-in-es-sclc-following-price-rethink/

NICE and Roche reach funding deal for Tecentriq in triple negative breast cancer

https://pharmaphorum.com/news/nice-okays-funding-for-roches-tecentriq-in-triple-negative-breast-cancer/

Novartis offers reimbursement options as EU backs costly SMA therapy

Novartis’ AveXis unit has said European regulators have approved its Zolgensma (onasemnogene abeparvovec) gene therapy for the rare

Novartis offers reimbursement options as EU backs costly SMA therapy

https://pharmaphorum.com/news/novartis-reimbursement-options-as-eu-approves-ultra-pricey-sma-drug/

Trump’s boasting overshadows supply deal for COVID-19 drugs

President Trump’s big agreement with a new US drugmaker to supply drugs for COVID-19 has been overshadowed by

Trump’s boasting overshadows supply deal for COVID-19 drugs

https://pharmaphorum.com/news/hopped-up-on-hydroxychloroquine-trump-signs-354m-deal-for-covid-19-drug-supply/

‘Delusional’ Shkreli refused prison release to fight coronavirus

Martin Shkreli, the pharma CEO once branded as America’s most hated man has been denied release from prison after a

‘Delusional’ Shkreli refused prison release to fight coronavirus

https://pharmaphorum.com/news/delusional-shkreli-refused-prison-release-to-fight-coronavirus/

Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug

The FDA has turned down Blueprint Medicines’ Ayvakit for more general use in gastrointestinal stromal tumour –

Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug

https://pharmaphorum.com/news/blueprint-pays-the-price-of-ayvakits-phase-3-miss-as-fda-rejects-drug/

COVID-19 vaccine row escalates as Macron calls meeting with Sanofi’s CEO

No-one even knows if it is possible to make a vaccine against COVID-19 and already there is an

COVID-19 vaccine row escalates as Macron calls meeting with Sanofi’s CEO

https://pharmaphorum.com/news/row-over-access-to-covid-19-jab-escalates-as-macron/

Verona says FDA backs plan to take COPD drug into phase 3

More than two years after first saying it would take its lead drug into a pivotal trial, Verona

Verona says FDA backs plan to take COPD drug into phase 3

https://pharmaphorum.com/news/verona-says-fda-backs-plan-to-take-copd-drug-into-phase-3/

Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel file

The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right

Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel file

https://pharmaphorum.com/news/celgene-investors-merger-payment-looks-rocky-as-fda-rejects-ide-cel-file/

NICE backs drugs for lymphoma and lung cancer from Roche and Pfizer

https://pharmaphorum.com/news/nice-backs-drugs-for-lymphoma-and-lung-cancer/

Study sets benchmark for cost of repurposed coronavirus drugs

Scientists have warned that the main drugs being repurposed for COVID-19 could end up being too expensive for

Study sets benchmark for cost of repurposed coronavirus drugs

https://pharmaphorum.com/news/study-sets-benchmark-for-cost-of-repurposed-coronavirus-drugs/

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

NICE has published final draft guidance recommending regular NHS funding for Roche’s Kadcyla (trastuzumab emtansine) in its newer use, for certain people

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

https://pharmaphorum.com/market-access-2/nice-backs-nhs-funding-for-roches-kadcyla-in-early-breast-cancer-use/

CHMP backs BMS’ first-in-class anaemia drug Reblozyl

Bristol-Myers Squibb has moved a step closer to EMA approval of Reblozyl, a therapy for anaemia that has

CHMP backs BMS’ first-in-class anaemia drug Reblozyl

https://pharmaphorum.com/news/chmp-backs-bms-first-in-class-anaemia-drug-reblozyl/

Search

Advanced Search

Trending

Latest News

More news